title: [A retrospective analysis of autologous peripheral blood hematopoietic stem cell mobilizations and collections in 149 multiple myeloma patients].
abstract: OBJECTIVE
  To analyze the results and influential factors of mobilization and harvesting of autologous peripheral blood stem cell in patients with multiple myeloma (MM).
  
  
  METHODS
  Retrospective analysis of peripheral blood stem cell collection data [CD34⁺ cells collected, successful mobilization rate (CD34⁺ cells≥2×10⁶/kg body weight), good mobilization rate (CD34⁺ cells≥5×10⁶/kg body weight)] of 149 multiple myeloma patients who were treated with cyclophosphamide (CTX) or E-CHOP (etoposide+ CTX+epirubicin+vindesine+prednisone) chemotherapy combined with G-CSF mobilization from January 1998 to March 2014. The relevance between gender, age, subtype, DS staging, ISS staging, treatment before mobilization, disease status at mobilization, regiment of mobilizationand the collection results was analyzed.
  
  
  RESULTS
  A total of 177 stem cell mobilizations were performed in 149 MM patients, the median CD34⁺ cells harvested were 3.20 (0.13-22.34)×10⁶/kg body weight (BW), successful mobilization rate and good mobilization rate were 74.5% and 27.5%, respectively. The single logistic regression analysis showed that gender, age （>60 ys vs ≤60 ys）, subtype, DS staging (III vs II+I), ISS staging (III vs II+I) and regiment of mobilization (E-CHOP+G-CSF vs ID-CTX+G-CSF) were not correlated with the cell collection or successful mobilization rate (P>0.05). However, successful collection rate of single harvest in old patients (age>60 ys) was lower (P<0.05), andthe good mobilization rate in patients at ISS stage III was lower (P<0.05). The collection results of patients with fewer cycles of treatment (treatment before mobilization ≤6 cycles) and optimal disease status (disease status at mobilization ≥partial remission) were much better. Analysis of logistic factors revealed that treatment efficacy before mobilization affected success rate of collection (P=0.006). Risk of collection failure in patients who received more than 6 cycles of treatment before mobilization was high (OR 3.57, 95% CI 1.45-8.78).
  
  
  CONCLUSIONS
  Gender, age, subtype, DS staging, ISS staging and mobilization regimen did not influence MM patients peripheral blood stem cell collection; but old patients may need twice mobilizations to collect sufficiently. Few cycles of treatment and stable disease status before mobilization is favorable to the mobilization and collection of peripheral blood stem cells.
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Guorong
authors.initials: G
authors.lastname: Wang
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Wenming
authors.initials: W
authors.lastname: Chen
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Yanchen
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Gao
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Guangzhong
authors.initials: G
authors.lastname: Yang
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Jinwei
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
authors.forename: Bianhong
authors.initials: B
authors.lastname: Yang
mesh_terms: D018952:Antigens, CD34; D003520:Cyclophosphamide; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells; D006801:Humans; D009101:Multiple Myeloma; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D000069585:Filgrastim